S-588410 is under clinical development by Shionogi & and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect S-588410’s likelihood of approval (LoA) and phase transition for Bladder Cancer took place on 17 Feb 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their S-588410 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

S-588410 overview

S-588410 is under development for the treatment of advanced or metastatic bladder cancer, non-small-cell lung cancer, refractory medulloblastoma, pediatric diffuse intrinsic pontine glioma, refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma. It is administered subcutaneously as an emulsion. The therapeutic candidate is a mixed peptide-cocktail vaccine of S-288310 and S-488410 comprising of five human leukocyte antigens (HLA)-A 2402-restricted epitope peptides derived from oncoantigen. The drug candidate is a new molecular entity. It was under development for the treatment of esophageal squamous cell carcinoma.

Shionogi & overview

Shionogi & (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.

Quick View S-588410 LOA Data

Report Segments
  • Innovator
Drug Name
  • S-588410
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Shionogi &
  • Originator: OncoTherapy Science
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.